Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Money does not smell of the mire whence it came; it has the glorious scent of what $will $be.
$TXTM $cent
Hmmm, $TXTM dotting the i's and crossing the t's ahead of anticipated news. Thanks for posting this due dily BBW.
IMO, filing a supplemental information report with OTCM at this juncture bodes well in more ways than one.
I just proved to you that Plandai SA (wholly owned subsidiary of Protext Pharma), is domiciled in South Africa, did you not read the information that was presented???
Also, you may want to re-read this PR for clarity:
Highlandernew, what you're overlooking is that $TXTM has two wholly owned subsidiaries.
IMO, the license/permit will be issued to Protext's subsidiary company, Plandai SA, or to the subsidiary company with an existing domicile in South Africa.
http://www.protextm.co/investors/lease_agreement
Take a look:
The $TXTM monster is awakening!!!
Bitcoin plays suckin' the life outta MJ plays and the rest of the OTC.
Freakin' insane crypto runs that we're seeing right now AP...
Maybe I'm a numbers guy...but 19.62 million more residents in #SA vs Canada equals 19.62 million more reasons to invest in S. African weeeeeeeeeeed >>>
The $medicinal $cannabis $prescription $business along with the ability to grow, cultivate & manufacture are part of the provisions and equation that the new framework encompass.
Would not be surprised to see $TXTM expand into all the canna-business possibilities arising from within the legal framework that has just last week taken effect!!!
$TXTM - Nice News Article Re: #SA Medical Cannabis:
Based on this $TXTM Press, and upon what the minutes 'should' corroborate, medicinal marijuana legislation has been finalized/approved.
The Medicines Act and the MCC's Guidelines have been adopted by #SA Parliament, and so now the legal framework/infrastructure to begin the issuance of Permits & Licenses has been implemented, choo-choo.
Love it...$TXTMedicinal...The legal framework to commence issuing medicinal cannabis research/growth & pharmacy licenses is now final and approved.
SA Parliament has put into motion that the MCC guidelines and the Medicines Act will be the framework for cannabis business in S. Africa.
https://www.iol.co.za/sundayindependent/analysis/medical-marijuana-bill-rejected-but-12157890
#TinusLange
#Houstonwehaveachiefpharmacist
https://ih.advfn.com/p.php?pid=nmona&article=76132676
$$OTTVector is Up...millions or nillions
Happy Thanksgiving Doog bro and all $TXTM champions.
Spending precious time with family is worth every second, and with the markets closed all day tomorrow and only open for a half day on Friday, there will be more time available for what matters most in life.
Cheers and catch ya's next week.
$$TXTM & this board looking great Chris! Take a look at the $TXTM buys to sells for today...virtually all buying, 154.81 buys to sells:
https://ih.advfn.com/stock-market/USOTC/protext-mobility-inc-TXTM/trades
Just a few 6's left...
'Tis the season for giving and gettin'
Cheers!
$$TXTM on High Alert - SA Parliamentary meeting is taking place tomorrow, November 22, to vote on the desirability of the Medical Innovation Bill.
The legislative framework will then be in place for $TXTM to receive their much anticipated medical marijuana license:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136365476
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136363900
<<<<< Major New $$TXTM Development >>>>>
I just read the minutes to last week's parliament meeting...WOW!
So...it looks like the Medical Innovation Bill is back on the parliamentary docket tomorrow, November 22.
The barriers of entry to 'haphazard' competition are multi-faceted. $TXTM is getting all their ducks in a row...in earnest now...IMO
Not only are there the stringent requirements of having a well-qualified and experienced Chief Pharmacist onboard, but mutually inclusively, the recent rescheduling of Cannabidiol in SA has put into operation, a/o November 17th, that strictly Cannabidiol (CBD) that is intended for therapeutic purposes' will be legal in South Africa:
https://www.gov.za/sites/default/files/41256_gon1261.pdf
The chief pharmacist's appointment legalizes and legitimizes $TXTM medicines platform... while haphazard competition would be operating illegally.
This is found within last week's Gazette. Pay particular attention to page 3
Honestly, I don't believe a noteable pharmacist with over 30 years of experience would accept becoming involved with an OTC scam.
I just started digging into our pharmacist, and IMO, this guy wouldn't be jeopardizing his family's future and his career.
Here is our pharmacist, Tinus Lange, on Facebook:
https://www.facebook.com/tinus.lange?lst=1031160067%3A100000098521959%3A1511198045
<<< $$TXTM NEWS >>> .0006 -- PROTEXT PHARMA APPOINTS CHIEF PHARMACIST AS PART OF TEAM TO OVERSEE CANNABIS MEDICINE OPERATIONS UPON ISSUANCE OF ANTICIPATED LICENSE IN SOUTH AFRICA
http://ih.advfn.com/p.php?pid=nmona&article=76132676
FLORIDA, USA -- November 20, 2017 -- InvestorsHub NewsWire -- Protext Pharma, Inc. (PINKSHEETS: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that it has appointed Mr. Tinus Lange to serve as a Chief Pharmacist for the company’s South African subsidiary. Under regulations approved earlier this month by the South Africa Medicine Control Council (MCC), all applications for licenses to grow, process or distribute medical cannabis must engage a qualified pharmacist to oversee the operations. Mr. Lange’s business information, pharmacy registration documents and security clearance, have been forwarded to the MCC as the final part of the Company’s application for a medical cannabis license.
Mr. Lange is a highly regarded pharmacist in the Mpumalanga province of South Africa, having owned and operated his own pharmacy since 1985. He graduated with the Pharmacology degree in 1982 from North West University and co-developed the first dispensing program ever used in South African pharmacies. Pharmacology is a life-passion for Mr. Lange with both his wife and daughter also being certified pharmacists
Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, “I am very pleased to have Mr. Lange’s join our operations as Chief Pharmacist to oversee the development of our cannabis medicines platform once our license is issued We will be working closely together to develop cannabis-based medicines that specifically address many of the disorders arising from the human endocannabinoid system. Being able to deliver a full-profile cannabis extract with up to 16 times the bioavailability of current extracts, while also being non-psychoactive, should give us a significant advantage in the marketplace. As with Plandaí’s Phytofare® catechin complex, similar claims will be made with the cannabinoid complex through fact-based research and clinical trials. We intend to conduct clinical trials to determine the effectiveness of the Phytofare® cannabinoid extract in treating inflammation. Increasing evidence suggests that the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands and metabolic enzymes, can regulate inflammation in a wide variety of cells including osteoblasts and synovial fibroblasts. An estimated 52.5 million adults in the United States suffer from forms of arthritis, making it the single biggest cause of disability. Two of the most common forms of arthritis, osteoarthritis and rheumatoid arthritis are associated with pain and joint damage due to loss of surface cartilage and bone within synovial joints. Both conditions lead to a poor quality of life, the inability to perform everyday tasks and, ultimately, permanent joint damage.”
Mr. Lang added, “This is a very exciting time in South Africa as just last Friday the MCC published a gazette officially changing their controlled substance schedule, down grading cannabidiol, when used for therapeutic purposes, from a schedule 6 drug to a schedule 4. I’m looking forward to working with the Company on developing its medical cannabis extract that I believe ultimately can help improve the quality of life of millions of people worldwide.”
Once the anticipated license is issued, the Company intends to commence cannabis operations at a facility in the District of White River, South Africa, where plants will be grown, cloned and cultivated to ensure a consistent chemical profile. The facility will incorporate an on-site laboratory designed and engineered to process live flower and plant material and, after separation and recovery of the oil-phase as a separate income stream, the final stage will be specific to the production of the Phytofare® complex containing cannabinoids, cannabinoid acids, terpenes, limonene and polyphenols. The resulting complex will be subjected to product profiling, analysis and bioavailability in order to determine efficacy and dosage. The Company will use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD acids and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the our extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract (schedule 4) with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Investors are encouraged to follow Protext using:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
CONTACT INFORMATION
Info@protextm.co
Contact: (435) 881-3611
About Protext Pharma, Inc.
Protext Pharma operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc. The Company is engaged in the research, clinical testing and commercialization of highly bioavailable botanical products—all-natural ingredients formulated for pharmaceutical applications and produced under pharma-grade conditions. Please visit http://www.protextm.co for further information.
About Plandai Biotechnology SA
Through its wholly owned subsidiary Plandai Biotechnology SA, the Company has the exclusive worldwide license to develop Phytofare® extracts from live plant materials including Phytofare® catechin complex, a highly bioavailable, and clinically proven antioxidant complex produced from live green tea leaves. Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours.
About Cannabis Biosciences
The Company is actively pursuing government licensing that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.
<<< $$TXTM NEWS >>> .0006 -- PROTEXT PHARMA APPOINTS CHIEF PHARMACIST AS PART OF TEAM TO OVERSEE CANNABIS MEDICINE OPERATIONS UPON ISSUANCE OF ANTICIPATED LICENSE IN SOUTH AFRICA
http://ih.advfn.com/p.php?pid=nmona&article=76132676
FLORIDA, USA -- November 20, 2017 -- InvestorsHub NewsWire -- Protext Pharma, Inc. (PINKSHEETS: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that it has appointed Mr. Tinus Lange to serve as a Chief Pharmacist for the company’s South African subsidiary. Under regulations approved earlier this month by the South Africa Medicine Control Council (MCC), all applications for licenses to grow, process or distribute medical cannabis must engage a qualified pharmacist to oversee the operations. Mr. Lange’s business information, pharmacy registration documents and security clearance, have been forwarded to the MCC as the final part of the Company’s application for a medical cannabis license.
Mr. Lange is a highly regarded pharmacist in the Mpumalanga province of South Africa, having owned and operated his own pharmacy since 1985. He graduated with the Pharmacology degree in 1982 from North West University and co-developed the first dispensing program ever used in South African pharmacies. Pharmacology is a life-passion for Mr. Lange with both his wife and daughter also being certified pharmacists
Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, “I am very pleased to have Mr. Lange’s join our operations as Chief Pharmacist to oversee the development of our cannabis medicines platform once our license is issued We will be working closely together to develop cannabis-based medicines that specifically address many of the disorders arising from the human endocannabinoid system. Being able to deliver a full-profile cannabis extract with up to 16 times the bioavailability of current extracts, while also being non-psychoactive, should give us a significant advantage in the marketplace. As with Plandaí’s Phytofare® catechin complex, similar claims will be made with the cannabinoid complex through fact-based research and clinical trials. We intend to conduct clinical trials to determine the effectiveness of the Phytofare® cannabinoid extract in treating inflammation. Increasing evidence suggests that the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands and metabolic enzymes, can regulate inflammation in a wide variety of cells including osteoblasts and synovial fibroblasts. An estimated 52.5 million adults in the United States suffer from forms of arthritis, making it the single biggest cause of disability. Two of the most common forms of arthritis, osteoarthritis and rheumatoid arthritis are associated with pain and joint damage due to loss of surface cartilage and bone within synovial joints. Both conditions lead to a poor quality of life, the inability to perform everyday tasks and, ultimately, permanent joint damage.”
Mr. Lang added, “This is a very exciting time in South Africa as just last Friday the MCC published a gazette officially changing their controlled substance schedule, down grading cannabidiol, when used for therapeutic purposes, from a schedule 6 drug to a schedule 4. I’m looking forward to working with the Company on developing its medical cannabis extract that I believe ultimately can help improve the quality of life of millions of people worldwide.”
Once the anticipated license is issued, the Company intends to commence cannabis operations at a facility in the District of White River, South Africa, where plants will be grown, cloned and cultivated to ensure a consistent chemical profile. The facility will incorporate an on-site laboratory designed and engineered to process live flower and plant material and, after separation and recovery of the oil-phase as a separate income stream, the final stage will be specific to the production of the Phytofare® complex containing cannabinoids, cannabinoid acids, terpenes, limonene and polyphenols. The resulting complex will be subjected to product profiling, analysis and bioavailability in order to determine efficacy and dosage. The Company will use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD acids and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the our extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract (schedule 4) with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Investors are encouraged to follow Protext using:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
CONTACT INFORMATION
Info@protextm.co
Contact: (435) 881-3611
About Protext Pharma, Inc.
Protext Pharma operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc. The Company is engaged in the research, clinical testing and commercialization of highly bioavailable botanical products—all-natural ingredients formulated for pharmaceutical applications and produced under pharma-grade conditions. Please visit http://www.protextm.co for further information.
About Plandai Biotechnology SA
Through its wholly owned subsidiary Plandai Biotechnology SA, the Company has the exclusive worldwide license to develop Phytofare® extracts from live plant materials including Phytofare® catechin complex, a highly bioavailable, and clinically proven antioxidant complex produced from live green tea leaves. Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours.
About Cannabis Biosciences
The Company is actively pursuing government licensing that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.
Reading is fundamental but understanding what your reading makes all the difference.
That said, perhaps you need to re-read my post.
My post was supposed to relate the significance of appointing a well-qualified pharmacist, as clearly the application is asking for the chief pharmacist's credentials. This is important since as we read in the application, the CP will be responsible for controlling the 'manufacture or import of medicinal cannabis'.
Also, the application specifies the following on page 13:
$$TXTM ~ Your assessment concerning the chief pharmacist's background appears to be on point.
I've expended some time perusing the MCC's Final Cannabis Guidelines together with the Application Forms, after seeing Friday's $TXTM tweet:
$TXTM Co. to engage Chief Pharmacist for cannabis operations in #SouthAfica. More to come.... #Medical #Cannabis
— Protext Pharma, Inc ($TXTM) (@protxtm) November 17, 2017
Hmmm...why is accumulation at an all time high?
Fact, $TXTM has traded in the same channel of .0005 to .0014 since early April 2017. During this time, the stock has been under constant accumulation, as indicated by the accumulation/distribution line's steady rise:
Aah but what you are missing is that GW Pharma started out as a biotechnology company without any revenues in sight, just like $TXTM / Protext Pharma.
Here is where it all changed for GW Pharma -- it's when the company was issued a license to research the uses of cannabis as a medicine:
Not even close to being factual! If the A/S were maxed out, then perhaps, but that is not case here with the $TXTM S/S.
Let's review your track record for this R/S drivel:
More fake news!
$TXTM / Protext Pharma has evidently and factually established a 'home base and corporate presence' in South Africa.
Here is some DD that you seem to have "overlooked":
When dealing with governments and passing legislation, a few months is a short period of time. Need I remind you, again, that no one has lied -- unless of course you wish to insinuate that the MCC or the Cannabis Working Group of the MCC have lied to the company. Didn't think so!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136225716
You act as if Rome was built in a day. This is a biotechnology company, and therefore just one very important development coming to fruition could set $TXTM and parent company $PLPL into massive runners.
Look what I just found:
http://ewn.co.za/2017/11/16/applications-to-grow-cannabis-for-medicinal-research-purposes-now-open?utm_source=dlvr.it&utm_medium=twitter
"Now with the MCC's framework being gazetted on Friday and being available to the public, people can apply for a license to grow their own cannabis for medicinal purposes."
Really?!?! The MCC and the SA parliament need to be in jail according to you...sure that makes sense how exactly?
We'll see on Friday what specific cannabis legislation becomes gazetted.
I think most are awaiting for this clarity that will come when the legislation is officially published/implemented and made available for public use.
'Heroes and Zeroes in the microcap world are one and the same...it just depends on the day'
$ICNB
It's called Due Diligence ("DD")!
And yes, the shareholder letter along with email thread with the MCC and the CANNABIS WORKING GROUP are in the public domain. This was issued in an official Press Release:
#Rukiddingme... what is criminal is the misinformation and libelous allegations that Jeffrey Greene's posse spews and disseminates.
How about you email Griffith Molewa from the MCC and inquire with him regarding $TXTM/ Protext Pharma. I know for a fact that you have not done so, but rather your contribution has been merely for comedic effect...at best!
GLTY
$TXTM - Aaaaaaaaand do you know who said that:
"We acknowledge the receipt of your application for research purposes on live cannabis plants and the recovery of phytonutrients . The permit will be issued pending the inspection of your premises. The Inspectors, herein copied, will contact you to arrange for the date of inspections'?
That was Griffith Molewa from the MCC on April 6th. Subsequently the site inspection occurred, and 'naturally' the company updated the shareholders in the manner as they were informed by the MCC, i.e, The permit will be issued pending the inspection of your premises.
#Real business = real developments occurring in real-time.
http://www.protextm.co/investors/shareholder_update
Bro... honestly...did you not pay attention in class?
There are no dates whatsoever being provided by the company. The SA parliament has established the following:
Hard to say exactly how much bid support there is for $OTTV
I see BMIC @ .0014... could be millions or "nillions" behind that 10k placeholder bid